ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 172 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2015. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $3,897,000 | +53.8% | 50,700 | +2.0% | 0.14% | +52.8% |
| Q1 2018 | $2,534,000 | -30.0% | 49,700 | -36.4% | 0.09% | -19.8% |
| Q4 2017 | $3,622,000 | -12.9% | 78,100 | 0.0% | 0.11% | -36.9% |
| Q3 2017 | $4,160,000 | -14.2% | 78,100 | 0.0% | 0.18% | +144.4% |
| Q2 2017 | $4,851,000 | -8.4% | 78,100 | 0.0% | 0.07% | -14.3% |
| Q1 2017 | $5,294,000 | +13.4% | 78,100 | +17.6% | 0.08% | +2.4% |
| Q4 2016 | $4,669,000 | -11.4% | 66,400 | -10.6% | 0.08% | -11.8% |
| Q3 2016 | $5,271,000 | +42.2% | 74,300 | -2.0% | 0.09% | +63.2% |
| Q2 2016 | $3,707,000 | +54.5% | 75,800 | +100.0% | 0.06% | +42.5% |
| Q1 2016 | $2,399,000 | -34.2% | 37,900 | +16.6% | 0.04% | -29.8% |
| Q4 2015 | $3,646,000 | +78.6% | 32,500 | +53.3% | 0.06% | +62.9% |
| Q3 2015 | $2,042,000 | – | 21,200 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |